A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Clinical trial NCT05894239 · RECRUITING

Trial details

NCT number: NCT05894239
Sponsor: Hoffmann-La Roche
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Breast Cancer

Start date: 2023-09-08
Primary completion: 2026-12-31
Enrollment: 230

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.